There was no correlation between the presence of KRAS mutations with the patients' gender, age (>70 years old versus ≤70 years old), stage at diagnosis, histological grade, mucinous status, PTEN loss and AREG-EREG expression (all p-values >0.05).
There was no correlation between the presence of BRAF and PIK3CA mutations with the patients' gender, age (>70 years old versus ≤70 years old), stage at diagnosis, tumour location, mucinous status, PTEN loss and AREG expression (in both cases all p-values >0.05).
EGFR protein expression was significantly associated with EGFR copy number and EGFR mutation, but not associated with gender, age, smoking status, lymph node metastasis or stage.
The detailed type of EGFR mutation did not correlate with gender, smoking status, p-stage, histological subtype, grade of tumour differentiation (data not shown).
There was no association of clarithromycin H.pylori resistance point mutations with patients' age or gender (data not shown).
Determining the somatic mutations of epidermal growth factor receptor (EGFR -pathway nEGFR -pathwaye key to effective treatmenetworkson-small cell lung cancer (NSCLC) wish theosine keyase inhibitors (TKIs).Theffective mutreatmentequencies and their association with gender, smoking history and histology was analysed and reported in this study.
Mutations of these four genes are associated with gender, smoking history and histology.
Evi expression levels showed no association with gender, age, TP53, IDH1 or IDH2 mutation status or with MGMT promoter methylation status (data not shown).
Here we report the mutation spectrum and the relationship of loss of STAG2 expression with gender, tumour grade, stage and chromosomal stability.
In addition, EGFR and KRAS, two driver mutations of lung carcinogenesis, are now well known for their particular distribution with gender and smoking history (Cooper et al, 2013).
